A phase I clinical trial evaluating the anti-EPHA3 monoclonal antibody ifabotuzumab in patients with recurrent glioblastoma demonstrated its efficacy in targeting the tumor microenvironment while sparing normal tissues48,49. This evidence concerns the gene EPHA3 and neoplasm.